The MMGT1 (also known as EMC10) antibody targets the MMGT1 protein, a member of the ER membrane protein complex (EMC) involved in membrane protein biogenesis and lipid homeostasis. MMGT1 is ubiquitously expressed and plays a critical role in the insertion of transmembrane domains during the co-translational assembly of multi-pass membrane proteins. Dysregulation of MMGT1 has been linked to metabolic disorders, neurodevelopmental conditions, and cancer progression.
Antibodies against MMGT1 are essential tools for studying its expression, localization, and interaction partners. They are widely used in techniques like Western blotting, immunofluorescence, and co-immunoprecipitation to explore MMGT1’s role in cellular processes such as endoplasmic reticulum (ER) stress response, protein folding, and lipid metabolism. Recent studies highlight its potential as a biomarker in diseases like obesity and hepatocellular carcinoma.
MMGT1 antibodies are typically validated for specificity across human, mouse, and rat models, aiding cross-species research. Challenges include distinguishing MMGT1 from homologous EMC subunits due to structural similarities, requiring rigorous validation. Ongoing research focuses on elucidating its mechanistic contributions to disease pathways, positioning MMGT1 as a promising therapeutic target. These antibodies thus serve as vital reagents for both basic and translational studies in cell biology and pathology.